Skip to main content
. Author manuscript; available in PMC: 2013 Feb 1.
Published in final edited form as: Eur J Pharm Biopharm. 2011 Nov 18;80(2):257–267. doi: 10.1016/j.ejpb.2011.10.023

Fig. 3.

Fig. 3

Cell viability of R4GFP cells transfected with different siRNA nanosomes (F1-F5), versus with lipofectamine and with IFN. The cells were cultured in 24-well plates and they were treated with different siRNA nanosomes, lipofectamine or with IFN-1 for three consecutive doses for a period of 12 days. The percentage of viable cells compared to the untreated cells during transfection was measured by MTT assay. The results represent mean ± standard deviation (n=5). (** and ## indicates p<0.001 of cell viability of R4GFP cells by F4 transfection compared to lipofectamine after 2nd and 3rd dose, respectively).